Company / Net Income
Haemonetics Net Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$167.7M
FY2024
5-year range
$43.4M / $167.7M
FY2020-FY2024
Trend
+42.6%
vs FY2023
Sector context
#57 of 158
Health Care
What the data says
At $168M, Haemonetics's net income ranks #57 of 158 in the Health Care sector. Net Income has increased for 3 consecutive years, from $43M in FY2021 to $168M in FY2024.
Based on SEC 10-K filings.
$168M in FY2024 with a 5-year CAGR of +17.0%.
Improved from $115M to $168M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +56.9%
- 5-Year CAGR
- +17.0%
- 10-Year CAGR
- -
Sector benchmark
#57 of 158 in Health CareTop 36% of 158This company $167.7M Sector average $475.0M
▼
-64.7% below sector average
Key checks
Key Insights
- Haemonetics's net income has grown for 3 consecutive years.
- 5-year CAGR of +17.0%, indicating consistent growth.
- In FY2024, net income increased 42.6% year-over-year.
- Ranks #57 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $167.7M | +42.6% |
| FY2023 | $117.6M | +1.9% |
| FY2022 | $115.4M | +166.1% |
| FY2021 | $43.4M | -45.4% |
| FY2020 | $79.5M | +3.8% |
| FY2019 | $76.5M | +39.1% |
| FY2018 | $55.0M | +20.7% |
| FY2017 | $45.6M | +273.5% |
| FY2016 | -$26.3M | +52.7% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026